1
Joseph Armstrong Martin, Keshab Sarma, David Bernard Smith, Mark Smith: Antiviral nucleoside derivatives. Roche Palo Alto, Brian L Buckwalter, January 25, 2005: US06846810 (86 worldwide citation)

The present invention relates to nucleoside derivatives for the treatment of Hepatitis C viral infections including compounds of formula I, pharmaceutical compositions comprising these compounds and methods for treatment or prophylaxis of Hepatitis C Virus mediated diseases employing said compounds ...


2
Byoung Kwon Chun, Jeremy Clark, Keshab Sarma, Peiyuan Wang: Antiviral nucleosides. Roche Palo Alto, Brian L Buckwalter, July 13, 2010: US07754699 (38 worldwide citation)

Compounds having the formula I wherein R1 is as herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, and processes for making the compounds of formula I


3
Joseph Armstrong Martin, Keshab Sarma, David Bernard Smith, Mark Smith: Anti-viral nucleosides. Roche Palo Alto, Brian L Buckwalter, May 27, 2008: US07378402 (24 worldwide citation)

4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (I:R1=R2=R3=R4=H) and prodrugs thereof are hepatitis C(HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for ...


4
Steven Lee Bender, Chris Allen Broka, Jeffrey Allen Campbell, Arlindo Lucas Castelhano, Lawrence Emerson Fisher, Robert Than Hendricks, Keshab Sarma: Matrix metalloprotease inhibitors. Syntex, Agouron Pharmaceuticals, Rohan Peries, August 3, 1999: US05932595 (12 worldwide citation)

The present invention relates to compounds of Formula I: ##STR1## that are matrix metalloprotease inhibitors, pharmaceutical compositions containing them, methods for their use and methods of preparing these compounds.


5
Keshab Sarma: Antiviral nucleosides. Roche Palo Alto, Brian L Buckwalter, January 12, 2010: US07645745 (11 worldwide citation)

Compounds having the formula I wherein R1 is as herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, processes for making the compounds and synthetic intermediates used in the process


6
Han Ma, Keshab Sarma, David Bernard Smith: Antiviral nucleosides. Roche Palo Alto, Brian L Buckwalter, August 7, 2012: US08236779 (11 worldwide citation)

Compounds having the formula I wherein R1, R2 and R3 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.


7
Terrence Joseph Connolly, Joseph Armstrong Martin, Anthony Prince, Keshab Sarma: Anhydrous crystalline 1-[4(S)-azido-2(S),3(R)-dihydroxy-4-(hydroxymethyl)-1(R)-cyclopentyl]cytosine hemisulfate as useful as an antiviral agent. Roche Palo Alto, Brian L Buckwalter, March 8, 2005: US06864244 (10 worldwide citation)

The present invention relates to the hemisulfate salt of 1-[4(S)-azido-2(S),3(R)-dihydroxy-4-(hydroxymethyl)-1(R)-cyclopentyl]cytosine (Ia) with improved stability and physical properties which facilitate manufacturing, handling and formulating I and polymorphic crystalline forms thereof.


8
Peter John Harrington, Stefan Hildbrand, Keshab Sarma: Process for the preparation of 4′-azido cytidine derivatives. Roche Palo Alto, Brian L Buckwalter, December 15, 2009: US07632940 (10 worldwide citation)

The invention relates to a novel process for the preparation of 4′-azido-cytidine (I) or a pharmaceutically accepted salt thereof. The compound of formula I is useful for treating virus mediated diseases, particularly for treating HCV mediated diseases.


9
Steven Berthel, Fariborz Firooznia, Daniel Fishlock, Jun Bae Hong, Yan Lou, Matthew Lucas, Timothy D Owens, Keshab Sarma, Zachary Kevin Sweeney, Joshua Paul Gergely Taygerly: Inhibitors of Brutons tyrosine kinase. Roche Palo Alto, George W Johnston, Dennis P Tramaloni, Jennifer L Kisko, October 30, 2012: US08299077 (7 worldwide citation)

This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formula I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclos ...


10
Steven D Axt, Keshab Sarma, Justin Vitale, Jiang Zhu, Bruce Ross, Suguna Rachakonda, Quingwu Jin, Byoung Kwon Chun: Preparation of nucleosides ribofuranosyl pyrimidines. Gilead Pharmasset, Cozen O Connor, December 16, 2014: US08912321 (2 worldwide citation)

The present process provides an improved method for the preparation of 4-amino-1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydrofuran-2-yl)-1H-pyrimidin-2-one of the formula (IV) which is a potent inhibitor of Hepatitis C Virus (HCV) NS5B polymerase.